Andrew Buchanan
Overview
Explore the profile of Andrew Buchanan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
743
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sampson J, Cannon D, Duan J, Epstein J, Sergeeva A, Katsamba P, et al.
J Mol Biol
. 2024 Jun;
436(16):168640.
PMID: 38844044
Computational free energy-based methods have the potential to significantly improve throughput and decrease costs of protein design efforts. Such methods must reach a high level of reliability, accuracy, and automation...
2.
Wossnig L, Furtmann N, Buchanan A, Kumar S, Greiff V
Drug Discov Today
. 2024 May;
29(7):104025.
PMID: 38762089
In the past 40 years, therapeutic antibody discovery and development have advanced considerably, with machine learning (ML) offering a promising way to speed up the process by reducing costs and...
3.
Puszkarska A, Taddese B, Revell J, Davies G, Field J, Hornigold D, et al.
Nat Chem
. 2024 May;
16(9):1436-1444.
PMID: 38755312
Several peptide dual agonists of the human glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R) are in development for the treatment of type 2 diabetes, obesity and their associated...
4.
Sampson J, Cannon D, Duan J, Epstein J, Sergeeva A, Katsamba P, et al.
bioRxiv
. 2024 May;
PMID: 38712280
Computational free energy-based methods have the potential to significantly improve throughput and decrease costs of protein design efforts. Such methods must reach a high level of reliability, accuracy, and automation...
5.
Satlawa T, Tarkowski M, Wrobel S, Dudzic P, Gawlowski T, Klaus T, et al.
PLoS Comput Biol
. 2024 Mar;
20(3):e1011881.
PMID: 38442111
Antibody-based therapeutics must not undergo chemical modifications that would impair their efficacy or hinder their developability. A commonly used technique to de-risk lead biotherapeutic candidates annotates chemical liability motifs on...
6.
Porebski B, Balmforth M, Browne G, Riley A, Jamali K, Furst M, et al.
Nat Biomed Eng
. 2023 Oct;
8(3):214-232.
PMID: 37814006
Developing therapeutic antibodies is laborious and costly. Here we report a method for antibody discovery that leverages the Illumina HiSeq platform to, within 3 days, screen in the order of...
7.
Aung E, Fairley C, Williamson D, Azzato F, Wigan R, Tran J, et al.
Microbiol Spectr
. 2023 Sep;
:e0079423.
PMID: 37671885
Early detection and treatment of syphilis will reduce the infectious period and transmission. We aimed to determine whether screening men who have sex with men (MSM) taking HIV pre-exposure prophylaxis...
8.
Paul D, Stern O, Vallis Y, Dhillon J, Buchanan A, McMahon H
Nat Commun
. 2023 Feb;
14(1):947.
PMID: 36854675
The ability of cells to manage consequences of exogenous proteotoxicity is key to cellular homeostasis. While a plethora of well-characterised machinery aids intracellular proteostasis, mechanisms involved in the response to...
9.
Masuda K, DeLozier A, Kolodsick J, Buchanan A, Pink A, Sun L, et al.
Eur J Dermatol
. 2022 Jul;
32(2):237-243.
PMID: 35866910
Background: Treatment with baricitinib in combination with topical corticosteroids previously showed greater improvements in itch and sleep versus placebo in adults with moderate-to-severe AD. Objectives: To assess whether improvements in...
10.
Chow E, Fairley C, Maddaford K, Schmidt T, Buchanan A, Tieosapjaroen W, et al.
Sex Health
. 2022 Apr;
19(2):148-150.
PMID: 35477514
Self-taking oropharyngeal swabs for sexually transmitted infections such as gonorrhoea and chlamydia has become more common during the COVID-19 pandemic to minimise the risk to healthcare workers. However, there have...